Breaking News Instant updates and real-time market news.

AAPL

Apple

$170.57

-4.44 (-2.54%)

, AMZN

Amazon.com

$1,176.76

8.4 (0.72%)

16:17
12/26/17
12/26
16:17
12/26/17
16:17

On The Fly: Top stock stories for Tuesday

Stocks opened slightly lower under the weight of Apple (AAPL) shares, which were down following a report about order cuts made by the company to its suppliers for the iPhone. The averages drifted throughout the day and closed in the red to begin a week that is sure to be marked by more slow news flow and tepid trading, due to being sandwiched between two Monday holidays. Meanwhile, bitcoin rallied back from its selloff last week and moved back above $16,000, helping give a boost to the growing list of crypto stock plays, which grew longer by at least one today. ECONOMIC EVENTS: In the U.S., the Dallas Fed manufacturing index bounced 10.3 points to 29.7 in December, topping the consensus forecast for a reading of 20. The Richmond Fed manufacturing index came in at 20, down from its prior reading of 30 and below the 21 consensus estimate. COMPANY NEWS: Shares of Apple (AAPL) slid 2.5% after a Taiwanese newspaper reportedly said the tech giant is telling suppliers that it is trimming its first quarter production expectations. A number of notable Apple suppliers - including Lumentum (LITE), Finisar (FNSR), Micron (MU), Qorvo (QRVO) and Universal Display (OLED) - were weak following the report as well... Amazon (AMZN) announced that Prime membership grew this holiday season, noting that "in one week alone, more than four million people started Prime free trials or began paid memberships to benefit from free two-day, one-day or same-day shipping." The company also noted that "tens of millions" of Alexa-enabled devices were sold worldwide during the holiday period. MAJOR MOVERS: Among the notable gainers was Sucampo Pharmaceutical (SCMP), which gained 5.9% to $18.00 after Mallinckrodt (MNK) announced a deal to acquire the company for $18 per share in a transaction valued at approximately $1.2B. Mallinckrodt shares were up a bit less than 1% following the deal announcement. Also higher as the newest beneficiary of attaching itself to the "crypto craze" was Pareteum (TEUM), which jumped 120% to $2.80 after announcing that it has completed development enabling it to add support of blockchain technology to its billing and settlement services. Among the noteworthy losers was Portola Pharmaceuticals (PTLA), which slid about 11% after the company announced that the FDA will extend its review of the biologics license application for AndexXa by 90 days. INDEXES: The Dow fell 7.85, or 0.03%, to 24,746.21, the Nasdaq lost 23.71, or 0.34%, to 6,936.25, and the S&P 500 slipped 2.84, or 0.11%, to 2,680.50.

AAPL

Apple

$170.57

-4.44 (-2.54%)

AMZN

Amazon.com

$1,176.76

8.4 (0.72%)

MNK

Mallinckrodt

$23.48

0.16 (0.69%)

SCMP

Sucampo

$18.00

1 (5.88%)

TEUM

Pareteum

$2.80

1.53 (120.47%)

QRVO

Qorvo

$65.90

-1.79 (-2.64%)

LITE

Lumentum

$49.70

-3.1 (-5.87%)

FNSR

Finisar

$20.46

-0.93 (-4.35%)

MU

Micron

$42.25

-1.87 (-4.24%)

OLED

Universal Display

$170.60

-4.95 (-2.82%)

  • 08

    Jan

  • 09

    Jan

  • 09

    Jan

  • 09

    Jan

  • 28

    Jan

  • 27

    Feb

  • 18

    Mar

AAPL Apple
$170.57

-4.44 (-2.54%)

12/21/17
MSCO
12/21/17
NO CHANGE
Target $200
MSCO
Overweight
iPhone X helping Apple accelerate share gains in China, says Morgan Stanley
Morgan Stanley analyst Katy Huberty said new data through the first 16 days of iPhone X availability in China show that adoption of the high-end device is on a faster pace than the iPhone 8 or 8 Plus, which she sees fueling an acceleration of Apple smartphone share gains. The analyst, who also noted that Google Trends data corroborate iPhone strength in China, said Apple remains her top pick entering 2018 and she keeps an Overweight rating on the stock with a $200 price target.
12/26/17
LSCM
12/26/17
NO CHANGE
LSCM
Buy
Lake Street says Knowles more likely than Himax to be impacted by Apple weakness
Lake Street analyst Jaeson Schmidt thinks Knowles (KN) is more likely to be impacted by concerns over iPhone X shipment weakness than Himax (HIMX), which is not immune but has the advantage of Android OEMs helping to backfill revenue that may be lost with Apple (AAPL). Amid the reports of concerns over weakness in first quarter iPhone X sales, he has Buy rating on the shares of both of the aforementioned Apple suppliers.
12/26/17
RSBL
12/26/17
NO CHANGE
RSBL
Rosenblatt sees no evidence of more Apple iPhone production cuts
Taiwanese media reports may be confusing the market and could be referring to previously mentioned iPhone 8/8 Plus production cuts, said Rosenblatt analysts, who added that they find no evidence in their research of further order cuts after the holiday season.
12/26/17
RILY
12/26/17
NO CHANGE
RILY
Apple estimates at limited risk after cautious iPhone report, says B. Riley FBR
B. Riley FBR analyst Craig Ellis noted the recent "divergent" reports on iPhone X demand from two Asian sources, namely Digitimes and Taiwan's Economic Daily News, pointing out that Digitimes seemed to imply a positive take about iPhone X forecasts while EDN discussed a post-holiday order cut made by the company to iPhone suppliers. Ellis said he would be opportunistic in adding to positions in some of the Apple supplier stocks being impacted by the EDN report, as he believes fundamentals continue to track toward consensus expectations, with upside possible. Ellis lists Broadcom (AVGO), Skyworks (SWKS), Applied Materials (AMAT) and Lam Research (LRCX) as among the Apple suppliers and semi equipment suppliers on which the firm maintains Buy ratings.
AMZN Amazon.com
$1,176.76

8.4 (0.72%)

12/19/17
KEYB
12/19/17
UPGRADE
Target $21
KEYB
Overweight
Brandywine Realty upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jordan Sadler upgraded Brandywine Realty (BDN) to Overweight from Sector Weight with a price target of $21. Sadler cites the company's execution in leasing, development discipline, and completion of its disposition program that positions the portfolio for same-store NOI growth that the management forecasts at 2%-5% through 2021. The analyst also notes a potential catalyst in Amazon (AMZN) choosing a location for its HQ2 - if Philadelphia, Austin, or North Virgina are selected, the company could benefit.
12/21/17
RBCM
12/21/17
NO CHANGE
Target $1200
RBCM
Outperform
Amazon revenue from Alexa could grow to $10-$11B by 2020, says RBC Capital
RBC Capital analyst Mark Mahaney said the firm's latest annual Alexa survey has left him more convinced of the potential long-term impact the voice-powered devices can have on Amazon. He expects Alexa's value proposition to increase in power as awareness and ownership rise and believes Amazon could see $10B-$11B in Alexa-related revenue by 2020. Mahaney maintains an Outperform rating and $1,200 price target on Amazon shares.
12/22/17
DBAB
12/22/17
NO CHANGE
DBAB
Strategic rationale for Home Depot buying XPO 'very clear,' says Deutsche Bank
Deutsche Bank analyst Amit Mehrotra noted that Recode reported that Home Depot (HD) has held internal talks about a potential acquisition bid for XPO Logistics (XPO), which is also said to be possibly being considered by Amazon (AMZN) as a takeover target. The news highlights the strategic and scarcity value of XPO's assets, said Mehrotra, who believes the company has "by far" the biggest heavy goods last mile business in the country. From a valuation standpoint, the analyst said his $110 price target is conservative and does not include any assumption of corporate tax reform, which would drive his target to $130. He maintains a Buy rating on XPO, whose stock is up 14% to $90 per share heading into the close.
12/26/17
SBSH
12/26/17
NO CHANGE
Target $110
SBSH
Buy
Citi ups XPO target to $110, sees takeover value closer to $120
Citi analyst Christian Wetherbee raised his price target for XPO Logistics (XPO) to $110 from $75 after Recode reported Friday that Home Depot (HD) has contemplated an acquisition of the company, partially as a defensive move to prevent Amazon (AMZN) from doing the same. In a research note titled "Buyer or Seller, There are Lots of Ways to Win," Wetherbee argues that XPO CEO Brad Jacobs is likely to be willing to maximize shareholder value either as a buyer or seller if the opportunity was right. Friday's article likely adds a takeout premium to XPO shares, at least near-term, the analyst adds. His new price target reflects this dynamic along with a "strong fundamental story." The analyst, however, believes a takeout bid would need to be higher, closer to $120 per share, due to the "significant potential value" XPO can create as a standalone company. Wetherbee keeps a Buy rating on XPO shares, which closed Friday up 14%, or $11.32, to $90.01.
MNK Mallinckrodt
$23.48

0.16 (0.69%)

12/26/17
WELS
12/26/17
NO CHANGE
WELS
Wells Fargo sees Sucampo deal as 'step in right direction' for Mallinckrodt
Wells Fargo analyst David Maris believes Mallinckrodt's (MNK) $1.2B acquisition of Sucampo (SCMP) is a step in the right direction for Mallinckrodt as it bolsters the company's rare disease pipeline, but Maris maintained a Market Perform rating on Mallinckrodt shares, believing investors will remain focused on the trajectory of Acthar, especially considering the drug's unexpected weakness in Q3.
12/26/17
RILY
12/26/17
DOWNGRADE
RILY
Neutral
Sucampo downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst David Buck downgraded Sucampo Pharmaceutals (SCMP) to Neutral after the company agreed to be acquired by Mallinckrodt (MNK) for $18 per share.
12/26/17
NOMU
12/26/17
NO CHANGE
Target $43
NOMU
Buy
Sucampo 'substantially' undervalued in $18 per share deal, says Nomura Instinet
Nomura Instinet analyst Christoper Marai believes Mallinckrodt's (MNK) $18 per share deal to buy Sucampo Pharmaceutals (SCMP) "substantially" undervalues the latter, noting that he attributes $29 per share in value to its Phase 2/3 asset VTS-270 for Niemann-Pick Disease Type C1 alone. The low deal price could create interest from other parties, though his talks with investors lead him to believe Sucampo is "fundamentally misunderstood" and that VTS-270 is under the radar, Marai tells investors. Marai maintains a Buy rating and $43 price target on Sucampo shares.
12/26/17
GSCO
12/26/17
NO CHANGE
GSCO
Neutral
Goldman says Mallinckrodt builds on rare disease pipeline with Sucampo deal
Goldman Sachs analyst Dana Flanders said Mallinckrodt's (MNK) deal for Sucampo (SCMP) further builds out the company's rare disease pipeline with two phase 3 assets while Amitiza, which is approved in three constipation indications, can act as a financial bridge before generic competition comes early next decade. He maintains a Neutral rating on Mallinckrodt, citing a near-term focus on the growth outlook for Acthar, but he noted that its pipeline optionality give the company a "growing number" of catalysts in 2018-2020.
SCMP Sucampo
$18.00

1 (5.88%)

TEUM Pareteum
$2.80

1.53 (120.47%)

QRVO Qorvo
$65.90

-1.79 (-2.64%)

11/14/17
OTRG
11/14/17
NO CHANGE
OTRG
Qorvo may be running Galaxy Note8's high-band power amplifier, says OTR Global
11/15/17
JPMS
11/15/17
NO CHANGE
Target $88
JPMS
Overweight
Qorvo shares remain undervalued, says JPMorgan
JPMorgan analyst Bill Peterson says that despite rallying 50% year-to-date, shares of Qorvo remain undervalued. The company's non-mobile, or Infrastructure and Defense Products, business continues to be underappreciated by investors, Peterson tells investors in a research note. He expects continued margin expansion and solid free cash flow generation and reiterates an Overweight rating on Qorvo with an $88 price target.
12/11/17
SBSH
12/11/17
NO CHANGE
SBSH
Citi 'getting more nervous' on semiconductors after Asia trip
Following a trip last week to Asia meeting with companies across the technology supply chain, Citi analyst Christopher Danely says he's "getting more nervous" on the semiconductor sector. While demand from the PC end market remains strong, the NAND market remains weak and data points on Apple's (AAPL) iPhone were mixed, Danely tells investors in a research note. The analyst saw signs of an inventory build and believes upside to consensus estimates is declining. He feels momentum is slowing in the semiconductor space. Danely's top pick is Microchip (MCHP) and he's also Buy-rated on Texas Instruments (TXN), Applied Materials (AMAT), Nvidia (NVDA), Skyworks (SWKS), ON Semiconductor (ON) and Micron (MU). The analyst's checks indicate slower than expected iPhone X and 8 demand but stronger iPhone 7 demand. He views this as bad for Skyworks and Qorvo (QRVO) and good for Analog Devices (ADI).
12/15/17
JPMS
12/15/17
NO CHANGE
JPMS
JPMorgan sees opportunities in Wireless Semiconductors, prefers Qorvo
JPMorgan analyst Bill Peterson believes the recent pullback in Wireless Semiconductor names, specifically Apple-exposed stocks, creates a good opportunity for investors to take long positions. The analyst sees the most upside in Qorvo (QRVO). He believes fears of production cuts and demand weakness are overblown. The December quarter and outlook for the March quarter are tracking to company expectations that have been built on conservative prospects for smartphone demand, Peterson tells investors in a research note.
LITE Lumentum
$49.70

-3.1 (-5.87%)

12/13/17
RSBL
12/13/17
NO CHANGE
RSBL
Lumentum weakness a buying opportunity, says Rosenblatt
12/13/17
RSBL
12/13/17
NO CHANGE
RSBL
Apple's investment in Finisar's new fab a neutral for Lumentum, says Rosenblatt
Rosenblatt analyst Jun Zhang said Apple's (AAPL) investment in Finisar's (FNSR) new fab is a neutral for Lumentum (LITE). Zhang said Finisar might not be able to supply the Android market as it sold all its potential capacity to Apple, reducing competition for Lumentum in that market. Further, the fab will take several quarters to prepare while the competitive landscape is not likely to change in 2018-2019, leaving Lumentum as the primary supplier to Apple, the analyst wrote.
12/18/17
NEED
12/18/17
NO CHANGE
Target $80
NEED
Strong Buy
Lumentum is top 2019 idea in Optical and Networking, says Needham
Needham analyst Alex Henderson keeps his Strong Buy rating on Lumentum with a price target of $80. Henderson says the company's dominant market shares in its core ROADM and Pump Laser businesses distinguish it from competition in the optical space challenged with growth and pricing factors. The analyst says the company is his "Single Best Idea" in the Optical and Networking sector thanks to its mix of Optical fundamentals and "exceptional opportunity" in 3D.
12/20/17
RILY
12/20/17
NO CHANGE
Target $89
RILY
Buy
Lumentum to supply China Telecom's ROADM deployment, says B. Riley FBR
B. Riley FBR analyst Dave Kang says multiple Chinese media sources indicate that China Telecom (CHA) plans to deploy a ROADM-based network in both Northern and Southern China after successfully deploying a similar network in the middle and lower sections of the Yangtze River region. The analyst believes Lumentum (LITE) will be the primary supplier of ROADMs, or reconfigurable optical add/drop multiplexers. He points out the company's management recently indicated that several products, including ROADMs, have been expedited by Chinese customers. Further, Kang expects China Mobile (CHL) to follow China Telecom's lead, most likely in mid-2018. The analyst thinks the Chinese ROADM cycle will be an important catalyst for Lumentum in 2018 and beyond. The stock is up 11c to $53.51 in afternoon trading. Kang has a Buy rating on Lumentum with an $89 price target.
FNSR Finisar
$20.46

-0.93 (-4.35%)

12/14/17
CHLM
12/14/17
NO CHANGE
Target $28
CHLM
Buy
Finisar price target raised to $28 after Apple award at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Finisar (FNSR) to $28 from $24 following Apple's (AAPL) award of $390M for VCSEL capacity/RD, which he believes is a "strong confirmation" of the market opportunity for 3D sensing, and a sign that the market is likely to be undersupplied for a number of quarters. The analyst reiterates a Buy rating on Finisar shares.
12/13/17
STFL
12/13/17
NO CHANGE
Target $26
STFL
Buy
Finisar price target raised to $26 after Apple award at Stifel
Stifel analyst Patrick Newton raised his price target for Finisar (FNSR) to $26 from $22 after the company announced it will receive $390M from Apple's (AAPL) Advanced Manufacturing Fund for building out its VCSEL production capabilities at its recently purchased Sherman facility. The analyst sees this as a win, and notes it further legitimizes 3D Sensing technology, eliminating any investor concern that Apple may revert to finger print sensors in the future as some data on iPhone X sell through has lagged expectations. He reiterates a Buy rating on Finisar's shares.
12/13/17
PIPR
12/13/17
NO CHANGE
Target $28
PIPR
Overweight
Finisar price target raised to $28 after Apple award at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target on Finisar (FNSR) to $28 from $22 after the company was awarded a $390M investment from Apple (AAPL) to scale VCSEL capacity, saying that he believes the deal solidifies a long-term relationship between the companies. Jensen has previously assumed Finisar only had 25% of the high-powered VCSEL for the iPhone X and Lumentum (LITE) had 75% of the high-power and 100% of the low-power VCSEL, but he now believes Finisar could capture significantly more share than previously expected, he tells investors.
MU Micron
$42.25

-1.87 (-4.24%)

12/20/17
FBCO
12/20/17
NO CHANGE
Target $60
FBCO
Outperform
Micron price target raised to $60 from $50 at Credit Suisse
Credit Suisse analyst John Pitzer raised his price target for Micron to $60 from $50 after the company reported Q1 results and guided Q2 well above consensus. The analyst reiterates an Outperform rating on the shares.
12/20/17
RSBL
12/20/17
NO CHANGE
Target $85
RSBL
Buy
Rosenblatt ups Micron price target to Street-high $85
Rosenblatt analyst Hans Mosesmann raised his price target for Micron Technology to $85 from $75 and reiterates a Buy rating on the shares following last night's better than expected results and guidance. The analyst believes "impressive demand and content dynamics" will continue to drive the memory cycle.
12/20/17
NEED
12/20/17
NO CHANGE
Target $76
NEED
Buy
Micron multiple should rise as investors appreciate secular shift, says Needham
Needham analyst Rajvindra Gill noted that Micron is trading well below its historical average P/E multiple of 8-10x, but thinks its multiple should rise as investors come to understand how the company benefits from the secular transition away from PCs and smartphones to high-performance computing applications, which brings with it higher capacity and favorable pricing. Gill maintains a Buy rating and $76 price target on Micron following the company's "record" quarter and guidance.
12/20/17
RSBL
12/20/17
NO CHANGE
Target $85
RSBL
Buy
Micron price target raised to $85 from $75 at Rosenblatt
OLED Universal Display
$170.60

-4.95 (-2.82%)

11/10/17
COWN
11/10/17
NO CHANGE
Target $195
COWN
Outperform
Universal Display price target raised to $195 from $155 at Cowen
Cowen analyst Robert Stone raised his price target on Universal Display (OLED) to $195 from $155 as he believes the company is poised for a strong 2018. The analyst cited several triggers, including its multi-year deal with Samsung (SSNLF) and the continued ramp of Apple's (AAPL) iPhone X. Stone reiterated his Outperform rating on Universal Display shares.
11/30/17
EVER
11/30/17
INITIATION
Target $225
EVER
Outperform
Universal Display initiated with an Outperform at Evercore ISI
Evercore ISI analyst C.J. Muse initiated Universal Display with an Outperform and $225 price target saying it is a pure-play in the fast growing OLED market. Muse sees a "significant opportunity" for the company as OLED smartphone penetration continues to growth, OLED TVs go mainstream on new disposition processes, and blue phosphorescent emitters are introduced. The analyst concludes by saying Universal Display's patent portfolio will allow the company to continue to dominate the market through material sales and a royalty/licensing model.
12/08/17
DBAB
12/08/17
NO CHANGE
Target $190
DBAB
Buy
Universal Display price target raised to $190 from $170 at Deutsche Bank
Deutsche Bank analyst Sidney Ho raised his price target for Universal Display to $190 after the company announced that is has signed a multi-year portfolio license and supply agreement with BOE Technology Group. The analyst believes the news bodes well for the company's Samsung negotiation. Ho keeps a Buy rating on Universal Display.
11/03/17
GABE
11/03/17
DOWNGRADE
GABE
Hold
Universal Display downgraded to Hold from Buy at Gabelli
Gabelli analyst Hendi Susanto downgraded Universal Display to Hold based on valuation and maintained a PMV of $125.

TODAY'S FREE FLY STORIES

CREE

Cree

$36.69

0.4 (1.10%)

12:54
01/23/18
01/23
12:54
01/23/18
12:54
Downgrade
Cree rating change  »

Cree downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PUBGY

Publicis

$17.85

0.03 (0.17%)

12:50
01/23/18
01/23
12:50
01/23/18
12:50
Hot Stocks
Publicis says undergoing 'destabilization attempt,' rejects allegations »

Publicis Groupe said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$61.67

0.42 (0.69%)

12:50
01/23/18
01/23
12:50
01/23/18
12:50
Options
Call buyers in Merck as shares move higher »

Call buyers in Merck as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 23

    Oct

12:50
01/23/18
01/23
12:50
01/23/18
12:50
General news
U.S. corporate bond update: the slate is thin with just a couple of issues »

U.S. corporate bond…

BCS

Barclays

$11.68

-0.06 (-0.51%)

12:46
01/23/18
01/23
12:46
01/23/18
12:46
Periodicals
Ex-Barclays banker recorded saying he destroyed key report, Bloomberg says »

Former Barclays top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.29

-0.16 (-0.30%)

12:43
01/23/18
01/23
12:43
01/23/18
12:43
Hot Stocks
Verizon giving 50 shares to employees following tax reform »

Verizon Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CBOE

Cboe Global Markets

$134.56

0.68 (0.51%)

12:42
01/23/18
01/23
12:42
01/23/18
12:42
Hot Stocks
Cboe Global Markets recognized in Hong Kong as approved stock exchange »

Cboe Global Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

RIG

Transocean

$11.68

-0.25 (-2.10%)

12:40
01/23/18
01/23
12:40
01/23/18
12:40
Options
Rolling action in Transocean calls »

Rolling action in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$6.30

0.01 (0.16%)

, JPM

JPMorgan

$114.46

0.13 (0.11%)

12:35
01/23/18
01/23
12:35
01/23/18
12:35
Hot Stocks
GoPro falls after Morgan Stanley downgrade cites limited strategic value »

Shares of GoPro (GPRO)…

GPRO

GoPro

$6.30

0.01 (0.16%)

JPM

JPMorgan

$114.46

0.13 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 07

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MET

MetLife

$53.56

-0.29 (-0.54%)

12:31
01/23/18
01/23
12:31
01/23/18
12:31
Hot Stocks
MetLife issues statement on court decision to dismiss appeal in SIFI litigation »

MetLife chairman,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 12

    Jun

CVE

Cenovus Energy

$10.43

0.04 (0.38%)

12:30
01/23/18
01/23
12:30
01/23/18
12:30
Options
Call buyers in Cenovus Energy as shares tick higher »

Call buyers in Cenovus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$135.52

0.31 (0.23%)

12:28
01/23/18
01/23
12:28
01/23/18
12:28
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend before news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AGN

Allergan

$187.32

-0.83 (-0.44%)

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Options
Allergan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Conference/Events
Leerink healthcare services analysts hold an analyst/industry conference call »

Healthcare Services…

VZ

Verizon

$53.23

-0.235 (-0.44%)

12:22
01/23/18
01/23
12:22
01/23/18
12:22
Periodicals
Verizon giving employees 50 shares of restricted stock, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CHFN

Charter Financial

$18.13

-0.12 (-0.66%)

12:21
01/23/18
01/23
12:21
01/23/18
12:21
Hot Stocks
Charter Financial raises quarterly dividend to 8c per share from 5c »

Charter Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$36.96

0.7 (1.93%)

, FOXA

21st Century Fox

$37.31

0.66 (1.80%)

12:20
01/23/18
01/23
12:20
01/23/18
12:20
Hot Stocks
21st Century Fox 'welcomes' part of CMA finding, 'disappointed' about plurality »

21st Century Fox (FOXA)…

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

SKYAY

Sky

$55.97

0.72 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 07

    Feb

$NSD

NASDAQ Market Internals

12:17
01/23/18
01/23
12:17
01/23/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Hot Stocks
Netflix's 'Mudbound' gets four Oscar noms, Amazon's 'The Big Sick' gets nod »

Films produced by Netflix…

NFLX

Netflix

$227.58

7.12 (3.23%)

AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 18

    Mar

$NYE

NYSE Market Internals

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$16.46

0.41 (2.55%)

12:15
01/23/18
01/23
12:15
01/23/18
12:15
Options
Hewlett Packard Enterprise put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

, TRV

Travelers

$145.27

5.92 (4.25%)

12:10
01/23/18
01/23
12:10
01/23/18
12:10
General news
On The Fly: Top stock stories at midday »

Stocks opened little…

NFLX

Netflix

$227.58

7.12 (3.23%)

TRV

Travelers

$145.27

5.92 (4.25%)

VZ

Verizon

$53.31

-0.15 (-0.28%)

JNJ

Johnson & Johnson

$143.58

-4.565 (-3.08%)

PG

Procter & Gamble

$89.11

-2.78 (-3.03%)

TSLA

Tesla

$351.56

1.54 (0.44%)

RMD

ResMed

$103.82

16.306 (18.63%)

WHR

Whirlpool

$171.12

4.47 (2.68%)

TWTR

Twitter

$22.96

-0.36 (-1.54%)

INSM

Insmed

$30.86

1.58 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 30

    Jan

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

UAL

United Continental

$76.96

0.09 (0.12%)

12:07
01/23/18
01/23
12:07
01/23/18
12:07
Technical Analysis
Technical Earnings Preview: United Continental has a potential bullish pattern »

Heading into earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

RHHBY

Roche

$30.79

0.1 (0.33%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Hot Stocks
Roche subsidiary treatment of gastric cancer granted FDA orphan status »

Genentech, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 23

    Feb

SQ

Square

$44.69

-0.6 (-1.32%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Options
Square call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.